A half-dozen biotechs are in the clinic with heat-shock protein (Hsp)-based drugs, but 2008 start-up Heat Biologics is putting a twist on that approach by developing Hsp vaccines capable of inducing and maintaining immune responses against cancer and other diseases. Read More
Impax Pharmaceuticals, of Hayward, Calif., received an award of up to $400,000 from The Michael J. Fox Foundation for development of its Parkinson's candidate, IPX066, an extended-release carbidopa-levodopa product. The funding will support a study of dosing conversion from CD-LD to IPX066 and an open-label extension safety study. Read More
Inovio Pharmaceuticals Inc., of Blue Bell, Pa., said that in a Phase I trial, its product VGX-3400X, a DNA vaccine, generated significant T-cell and antibody responses against avian H5N1 delivered with intramuscular electroporation. Read More
Lpath Inc., of San Diego, received U.S. Patent No. 7,956,173, which covers composition of matter related to sonepcizumab, the drug substance in the firm's lead compounds, iSONEP and ASONEP Read More
WASHINGTON – An advisory committee voted unanimously for accelerated approval for two lymphoma indications for Seattle Genetics Inc.'s Adcetris, but the company has its work cut out for it if it hopes to get FDA approval by its Aug. 30 PDUFA date. Read More
Founded only last year to develop cancer drugs that work by attacking cancer stem cells, Verastem Inc. already has closed its second round on funding, bringing in $32 million in a Series B. Read More
